KARIPHARMA
ActiveSummary
KARIPHARMA has been active since 2003 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €632,727 and a net result of €108,353. Equity is growing by about 4.4% per year across the filed financial years. Its solvency ranks better than 79% of 2,795 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
01-03
Gazette deed
Appointment: PHARMADA (director)Permanent representative: BROECHOVEN Kristel · Legal-form conversion · Purpose change11 facts ▸
- General meeting, “buitengewone algemene vergadering” (deed in Dutch)
- Legal-form conversion, “besloten vennootschap(BV)” (deed in Dutch)
- Other provision, “verslag bestuursorgaan over voorwerpwijziging, dossier van de notaris” (deed in Dutch)
- Purpose change
- Capital conversion, “artikel 39,§2,tweede lid wet van 2019-03-23, niet-opgevraagde inbrengen” (deed in Dutch)
- Other provision, “opheffing statutair onbeschikbare eigen vermogensrekening, middelen beschikbaar voor uitkering” (deed in Dutch)
- Other provision, “bij uittreksel, voormelde beslissingen” (deed in Dutch)
- Director appointment, PHARMADA (director (not named in the articles))
- Permanent representative, BROECHOVEN Kristel
- Registered office clause, “1742 Ternat,Kerkstraat 14” (deed in Dutch)
- Power of attorney
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.